Longitudinal adherence with fecal occult blood test screening in community practice
- PMID: 20843880
- PMCID: PMC2939414
- DOI: 10.1370/afm.1133
Longitudinal adherence with fecal occult blood test screening in community practice
Abstract
Purpose: Although screening with fecal occult blood testing (FOBT) reduces colorectal cancer (CRC) mortality, its effectiveness may diminish if patients do not adhere with repeated screenings. Among patients who had previously engaged in FOBT screening, we assessed subsequent adherence with FOBT screening.
Methods: We assessed longitudinal adherence with biennial FOBT screening (every other year) within a cohort of patients enrolled in an integrated Washington State health plan. Among 11,110 patients who participated in FOBT screening during a 2-year baseline period (2000-2001), we ascertained CRC screening use during a subsequent 2-year observation period (2002-2003). We used multinomial logistic regression to identify patient characteristics associated with higher incidence of repeat CRC screening (with or without FOBT) relative to patients who received no CRC screening.
Results: Despite prior participation in FOBT screening, less than one-half of patients (44.4%; 95% CI, 42.9%-45.8%) completed FOBT screening during the 2-year observation period. Although 8.8% of patients (95% CI, 8.0%-9.7%) received other CRC tests without FOBT during the observation period, nearly one-half, 46.8% (95% CI, 45.3%-48.4%), received no CRC screening. After adjustment for other patient characteristics, receipt of a preventive health examination was strongly associated with FOBT adherence relative to no CRC screening (adjusted relative rate ratio = 11.16; 95% CI, 9.61-12.96).
Conclusions: Longitudinal adherence with FOBT screening was low in this insured population, potentially compromising its effectiveness in population CRC mortality reduction. Interventions to promote adherence may be necessary to achieve high effectiveness in population-based FOBT screening programs.
Figures
Similar articles
-
Longitudinal Adherence to Immunochemical Fecal Occult Blood Testing vs Guaiac-based FOBT in an Organized Colorectal Cancer Screening Program.Cancer Prev Res (Phila). 2019 May;12(5):327-334. doi: 10.1158/1940-6207.CAPR-18-0091. Epub 2019 Mar 19. Cancer Prev Res (Phila). 2019. PMID: 30890542
-
Adherence to repeat fecal occult blood testing in an urban community health center network.J Community Health. 2013 Oct;38(5):829-33. doi: 10.1007/s10900-013-9685-x. J Community Health. 2013. PMID: 23546555
-
Participation in colorectal cancer screening: a review.J Natl Cancer Inst. 1997 Oct 1;89(19):1406-22. doi: 10.1093/jnci/89.19.1406. J Natl Cancer Inst. 1997. PMID: 9326910 Review.
-
Impact of continued mailed fecal tests in the patient-centered medical home: Year 3 of the Systems of Support to Increase Colon Cancer Screening and Follow-Up randomized trial.Cancer. 2016 Jan 15;122(2):312-21. doi: 10.1002/cncr.29734. Epub 2015 Oct 21. Cancer. 2016. PMID: 26488332 Free PMC article. Clinical Trial.
-
Review in depth and meta-analysis of controlled trials on colorectal cancer screening by faecal occult blood test.Eur J Gastroenterol Hepatol. 2006 Apr;18(4):427-33. doi: 10.1097/00042737-200604000-00018. Eur J Gastroenterol Hepatol. 2006. PMID: 16538116 Review.
Cited by
-
Protocol paper for an implementation science approach to promoting colorectal cancer screening in Federally Qualified Health Center clinics: A stepped-wedge, multilevel intervention trial.Res Sq [Preprint]. 2024 Jul 18:rs.3.rs-4558718. doi: 10.21203/rs.3.rs-4558718/v1. Res Sq. 2024. PMID: 39070625 Free PMC article. Preprint.
-
N6-methyladenosine levels in peripheral blood RNA: a potential diagnostic biomarker for colorectal cancer.Cancer Cell Int. 2024 Mar 5;24(1):96. doi: 10.1186/s12935-024-03289-2. Cancer Cell Int. 2024. PMID: 38439072 Free PMC article.
-
Next-generation Multi-target Stool DNA Panel Accurately Detects Colorectal Cancer and Advanced Precancerous Lesions.Cancer Prev Res (Phila). 2024 Mar 4;17(3):119-126. doi: 10.1158/1940-6207.CAPR-23-0285. Cancer Prev Res (Phila). 2024. PMID: 38224564 Free PMC article.
-
Facilitating Equitable, High-Quality Cancer Screening in the Post-COVID-19 Era.JAMA Netw Open. 2022 Jun 1;5(6):e2215496. doi: 10.1001/jamanetworkopen.2022.15496. JAMA Netw Open. 2022. PMID: 35657630 Free PMC article. No abstract available.
-
Improving Adenoma Detection Rates: The Role of the Fecal Immunochemical Test.Cureus. 2021 Apr 9;13(4):e14382. doi: 10.7759/cureus.14382. Cureus. 2021. PMID: 33976998 Free PMC article.
References
-
- Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328(19):1365–1371. - PubMed
-
- Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000;343(22):1603–1607. - PubMed
-
- Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348(9040):1472–1477. - PubMed
-
- Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348(9040):1467–1471. - PubMed
-
- Inventory of Colorectal Cancer Screening Activities in International Cancer Screening Network (ICSN) Countries. May 2008. National Cancer Institute Web Site. http://appliedresearch.cancer.gov/icsn/colorectal/screening.html. Accessed Jun 1, 2009.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical